In an Australian first, Vitura announced that its joint venture, Cortexa, had started batch manufacturing of GMP LaNeo MDMA 40mg capsules to support both clinical trials and clinical use under the ...
In an Australian first, Vitura announced that its joint venture, Cortexa, had started batch manufacturing of GMP LaNeo MDMA 40mg capsules to support both clinical trials and clinical use under the ...
In an Australian first, Vitura announced that its joint venture, Cortexa, had started batch manufacturing of GMP LaNeo MDMA 40mg capsules to support both clinical trials and clinical use under the ...
In an Australian first, Vitura announced that its joint venture, Cortexa, had started batch manufacturing of GMP LaNeo MDMA 40mg capsules to support both clinical trials and clinical use under the ...
In an Australian first, Vitura announced that its joint venture, Cortexa, had started batch manufacturing of GMP LaNeo MDMA 40mg capsules to support both clinical trials and clinical use under the ...
In an Australian first, Vitura announced that its joint venture, Cortexa, had started batch manufacturing of GMP LaNeo MDMA 40mg capsules to support both clinical trials and clinical use under the ...
Ltd. (“Cortexa”), is proud to have commenced batch manufacturing of GMP LaNeo® MDMA 40mg capsules to support both clinical trials and clinical use under the TGA’s Authorised Prescriber pathway. In ...
Ltd. (“Cortexa”), is proud to have commenced batch manufacturing of GMP LaNeo® MDMA 40mg capsules to support both clinical trials and clinical use under the TGA’s Authorised Prescriber pathway. In ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback